The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Latest Information Update: 01 Jul 2024
At a glance
- Drugs PEPIDH1M (Primary) ; Diphtheria toxoid; Montanide ISA-51; Temozolomide; Tetanus toxoid
- Indications Glioma; Medulloblastoma
- Focus Adverse reactions
- Acronyms PRiME
- 04 Jun 2024 Results(n=42) assessing the safety and feasibility of a novel peptide vaccine targeting pp65 (PEP-CMV) in children/young adults with recurrent medulloblastoma and HGG, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 31 Mar 2023 Planned End Date changed from 1 Dec 2024 to 1 Apr 2025.
- 31 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Apr 2023.